Small molecules as kinetoplastid specific proteasome inhibitors for leishmaniasis: a patent review from 1998 to 2021

The ultimate fate determinants of drug induced cell-death mechanisms in trypanosomatids

(2021) Payel Das et al.   International Journal for Parasitology-Drugs and Drug Resistance

Synthetic molecules as DprE1 inhibitors: A patent review

(2021) Mohd. Imran et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Potential therapeutic targets shared between leishmaniasis and cancer

(2021) Sajad Rashidi et al.   PARASITOLOGY

2-aminobenzimidazoles for leishmaniasis: From initial hit discovery to in vivo profiling

(2021) Rafael Augusto Alves Ferreira et al.   PLoS Neglected Tropical Diseases

An Overview on the Therapeutics of Neglected Infectious Diseases—Leishmaniasis and Chagas Diseases

(2021) Brindha J et al.   Frontiers in Chemistry

Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral Leishmaniasis

(2021) Michael Thomas et al.   JOURNAL OF MEDICINAL CHEMISTRY

Geographical Variability in Paromomycin Pharmacokinetics Does Not Explain Efficacy Differences between Eastern African and Indian Visceral Leishmaniasis Patients

(2021) Luka Verrest et al.   CLINICAL PHARMACOKINETICS

Mucormycosis medications: a patent review

(2021) Mohd. Imran et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Identification of Resistance Determinants for a Promising Antileishmanial Oxaborole Series

(2021) Magali Van den Kerkhof et al.   Microorganisms

Microbial proteasomes as drug targets

(2021) Hao Zhang et al.   PLoS Pathogens

An Insight into the Current Perspective and Potential Drug Targets for Visceral Leishmania (VL)

(2020) Rani Mansuri et al.   CURRENT DRUG TARGETS

In Vitro and in Vivo Activity of mTOR Kinase and PI3K Inhibitors Against Leishmania donovani and Trypanosoma brucei

(2020) Trong-Nhat Phan et al.   MOLECULES

Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases

(2020) Advait Nagle et al.   JOURNAL OF MEDICINAL CHEMISTRY

Viral entry and the ubiquitin‐proteasome system

(2020) Seth M. Schneider et al.   CELLULAR MICROBIOLOGY

Proteasome, a Promising Therapeutic Target for Multiple Diseases Beyond Cancer

(2020) Yu Cao et al.   Drug Design Development and Therapy

Leishmanicidal therapy targeted to parasite proteases

(2019) Patrícia de Almeida Machado et al.   LIFE SCIENCES

Lactacystin: first-in-class proteasome inhibitor still excelling and an exemplar for future antibiotic research

(2019) Satoshi Ōmura et al.   JOURNAL OF ANTIBIOTICS

Current and emerging medications for the treatment of leishmaniasis

(2019) Jaya Chakravarty et al.   EXPERT OPINION ON PHARMACOTHERAPY

Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition

(2019) Susan Wyllie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Pharmacokinetics and pharmacodynamics of the nitroimidazole DNDI-0690 in mouse models of cutaneous leishmaniasis

(2019) Gert-Jan Wijnant et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The proteasome as a target for protozoan parasites

(2019) Stanley C. Xie et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Clinical and epidemiological characteristics of cutaneous leishmaniasis in Sri Lanka

(2018) Devika Iddawela et al.   BMC INFECTIOUS DISEASES

Emerging therapeutic targets for treatment of leishmaniasis

(2018) Shyam Sundar et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis

(2018) Susan Wyllie et al.   NATURE

Leishmania treatment and prevention: Natural and synthesized drugs

(2018) Adnan A. Bekhit et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Identification of GSK3186899/DDD853651 as a Preclinical Development Candidate for the Treatment of Visceral Leishmaniasis

(2018) Michael G. Thomas et al.   JOURNAL OF MEDICINAL CHEMISTRY

Drug Discovery for Kinetoplastid Diseases: Future Directions

(2018) Srinivasa P. S. Rao et al.   ACS Infectious Diseases

Targeting proteasomes in infectious organisms to combat disease

(2017) Betsaida Bibo-Verdugo et al.   FEBS Journal

The history of leishmaniasis

(2017) Dietmar Steverding   Parasites & Vectors

In Vitro Immunomodulatory Activity of a Transition-State Analog Inhibitor of Human Purine Nucleoside Phosphorylase in Cutaneous Leishmaniasis

(2017) Natália Barbosa Carvalho et al.   Journal of Immunology Research

Pharmacological inhibition of p110δ subunit of PI3K confers protection against experimental leishmaniasis

(2016) Forough Khadem et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness

(2016) Shilpi Khare et al.   NATURE

Proteasome inhibition combats kinetoplastid infections

(2016) Sarah Crunkhorn   NATURE REVIEWS DRUG DISCOVERY

Cutaneous Leishmaniasis: Recent Developments in Diagnosis and Management

(2015) Henry J. C. de Vries et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Topical Paromomycin with or without Gentamicin for Cutaneous Leishmaniasis

(2013) Afif Ben Salah et al.   NEW ENGLAND JOURNAL OF MEDICINE

Leishmaniasis Worldwide and Global Estimates of Its Incidence

(2012) Jorge Alvar et al.   PLoS One

Drug Susceptibility in Leishmania Isolates Following Miltefosine Treatment in Cases of Visceral Leishmaniasis and Post Kala-Azar Dermal Leishmaniasis

(2012) Vasundhra Bhandari et al.   PLoS Neglected Tropical Diseases

Paromomycin for the Treatment of Visceral Leishmaniasis in Sudan: A Randomized, Open-Label, Dose-Finding Study

(2010) Ahmed M. Musa et al.   PLoS Neglected Tropical Diseases

The p110  Isoform of Phosphatidylinositol 3-Kinase Controls Susceptibility to Leishmania major by Regulating Expansion and Tissue Homing of Regulatory T Cells

(2009) D. Liu et al.   JOURNAL OF IMMUNOLOGY